MPM Capital

Entrada Therapeutics, Inc., a biotechnology company, engages in the treatment of diseases through the intracellular delivery of biologic. The company enables intracellular delivery of proteins, peptides, and nucleic acids and allows development of programs across intracellular target classes. Its Intracellular enzyme replacement therapy (IC-ERT) is a medical treatment that corrects an enzyme deficiency in the cell, Protein-Protein Interaction Inhibitors. The company was founded in 2016 and is based in Boston, Massachusetts.

Aktis Oncology is a biotechnology company focused on developing targeted radiopharmaceuticals for the treatment of various solid tumor cancers. The company has created proprietary platforms that generate tumor-targeting agents optimized for alpha radiotherapy. These agents are engineered to achieve high penetration into tumors and prolonged residence time, allowing for effective tumor elimination while reducing side effects associated with treatment. Additionally, Aktis Oncology's innovative approach enables clinicians to visualize and confirm target engagement before administering therapeutic radioisotopes, enhancing the precision of cancer treatment.

ElevateBio, LLC, based in Cambridge, Massachusetts, is a holding company focused on the development of cell and gene-based therapies. Established in 2017, ElevateBio operates a portfolio of subsidiary companies that aim to create innovative treatments for cancer and viral infections. The company partners with leading scientists and inventors to foster its portfolio and has established a centralized facility designed to streamline the translation of research and development into commercially viable therapies. This integrated approach enables the efficient development, manufacturing, and commercialization of life-transforming medicines, ultimately helping to provide patients with effective treatments for severe diseases.

Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna’s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions.

Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cancer immunotherapies. Founded in 2017, the company is advancing a pipeline of therapeutic candidates designed to stimulate the immune system specifically within the tumor microenvironment. Utilizing its proprietary PREDATOR platform, Werewolf Therapeutics engineers conditionally activated molecules known as INDUKINE, which remain inactive in peripheral tissues but activate selectively in the presence of tumors. This targeted approach aims to enhance both adaptive and innate immune responses, addressing limitations associated with traditional proinflammatory therapies. Through its research and development efforts, Werewolf Therapeutics is committed to transforming cancer treatment.

Cullinan Pearl, a subsidiary of Cullinan Oncology, focuses on developing innovative cancer therapies, specifically targeting Epidermal Growth Factor Receptor (EGFR) exon 20 mutations through its orally available tyrosine kinase inhibitor. The company is part of a broader strategy to create a diverse portfolio of oncology therapeutics, relying on a combination of internal research and collaborative efforts with academic institutions and pharmaceutical companies. This approach allows Cullinan Pearl to efficiently advance its drug development programs, with a commitment to rapidly discontinue any projects that show limited potential based on early research findings. As part of its ongoing initiatives, Cullinan Pearl collaborates with Cullinan Oncology to support the development and commercialization of its therapies.

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapies. The company was founded in 2017 and is based in Waltham, Massachusetts.

Cullinan Pearl, a subsidiary of Cullinan Oncology, focuses on developing innovative cancer therapies, specifically targeting Epidermal Growth Factor Receptor (EGFR) exon 20 mutations through its orally available tyrosine kinase inhibitor. The company is part of a broader strategy to create a diverse portfolio of oncology therapeutics, relying on a combination of internal research and collaborative efforts with academic institutions and pharmaceutical companies. This approach allows Cullinan Pearl to efficiently advance its drug development programs, with a commitment to rapidly discontinue any projects that show limited potential based on early research findings. As part of its ongoing initiatives, Cullinan Pearl collaborates with Cullinan Oncology to support the development and commercialization of its therapies.

ITeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics for cancer treatment. Founded in 2011 and headquartered in Gosselies, Belgium, with operational ties to Cambridge, Massachusetts, the company leverages its expertise in tumor immunology to create small molecule immunomodulators. Its product pipeline includes EOS-850, an antagonist of the adenosine A2a receptor, currently in an open-label Phase 1/2a clinical trial for adult patients, and EOS-448, which targets the TIGIT receptor and is also in a Phase 1/2a clinical trial. ITeos aims to enhance the effectiveness of cancer therapies by targeting resistance mechanisms within the tumor microenvironment, thereby improving the clinical outcomes of existing treatment modalities and newer immunotherapies.

ElevateBio, LLC, based in Cambridge, Massachusetts, is a holding company focused on the development of cell and gene-based therapies. Established in 2017, ElevateBio operates a portfolio of subsidiary companies that aim to create innovative treatments for cancer and viral infections. The company partners with leading scientists and inventors to foster its portfolio and has established a centralized facility designed to streamline the translation of research and development into commercially viable therapies. This integrated approach enables the efficient development, manufacturing, and commercialization of life-transforming medicines, ultimately helping to provide patients with effective treatments for severe diseases.

Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna’s proprietary platform combines novel technology to create oRNAs that drive protein expression with validated and unique delivery solutions.

Triplet Therapeutics, Inc. develops therapeutics and treatments for triplet disorders. It develops treatment for repeat expansion disorders, including Huntington’s disease, myotonic dystrophy, and spinocerebellar ataxias. Triplet Therapeutics, Inc. was formerly known as rzna, Inc. The company was founded in 2018 and is based in Cambridge, Massachusetts.

Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cancer immunotherapies. Founded in 2017, the company is advancing a pipeline of therapeutic candidates designed to stimulate the immune system specifically within the tumor microenvironment. Utilizing its proprietary PREDATOR platform, Werewolf Therapeutics engineers conditionally activated molecules known as INDUKINE, which remain inactive in peripheral tissues but activate selectively in the presence of tumors. This targeted approach aims to enhance both adaptive and innate immune responses, addressing limitations associated with traditional proinflammatory therapies. Through its research and development efforts, Werewolf Therapeutics is committed to transforming cancer treatment.

Oncorus, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative viral immunotherapies for cancer treatment. The company's lead candidate, ONCR-177, utilizes an oncolytic herpes simplex virus type 1 platform and is currently in Phase I clinical trials aimed at treating various cancers. In addition to ONCR-177, Oncorus is advancing the ONCR-GBM program for brain cancer and exploring synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has entered a collaboration with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 in combination with Merck’s immunotherapy. Founded in 2015 and headquartered in Cambridge, Massachusetts, Oncorus is committed to advancing cancer care and has pledged to support cancer research and healthcare initiatives in developing regions through corporate philanthropy.

Twentyeight-Seven, Inc. is a biotechnology company based in Watertown, Massachusetts, specializing in the development of small molecules that modulate microRNAs (miRNAs) by targeting the proteins that interact with these molecules. Their innovative approach focuses on using short non-coding RNAs to inhibit gene expression, suppress mRNA translation, and promote mRNA decay. By targeting miRNAs that play a critical role in cancer initiation, progression, and metastasis, Twentyeight-Seven aims to create effective therapeutic solutions for cancer treatment.

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapies. The company was founded in 2017 and is based in Waltham, Massachusetts.

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapies. The company was founded in 2017 and is based in Waltham, Massachusetts.

TriNetX, Inc. is a global health research network that facilitates collaboration among healthcare organizations, biopharmaceutical companies, and contract research organizations. The company provides a platform that enables researchers to analyze patient populations and derive real-world evidence, thereby enhancing trial design and improving site selection. Key offerings include TriNetX Live, a cloud-based solution for real-time analytics; TriNetX Research, which delivers longitudinal clinical data; and TriNetX Download, a platform for accessing real-world clinical data. Additionally, TriNetX features Attract Trials for data alignment in collaboration, Natural Language Processing for extracting clinical insights from physician documentation, and specialized tools for oncology research. Established in 2013 and headquartered in Cambridge, Massachusetts, TriNetX also has offices in Sydney, London, and Sao Paulo, and maintains compliance with HIPAA and GDPR regulations.

Entrada Therapeutics, Inc., a biotechnology company, engages in the treatment of diseases through the intracellular delivery of biologic. The company enables intracellular delivery of proteins, peptides, and nucleic acids and allows development of programs across intracellular target classes. Its Intracellular enzyme replacement therapy (IC-ERT) is a medical treatment that corrects an enzyme deficiency in the cell, Protein-Protein Interaction Inhibitors. The company was founded in 2016 and is based in Boston, Massachusetts.

Twentyeight-Seven, Inc. is a biotechnology company based in Watertown, Massachusetts, specializing in the development of small molecules that modulate microRNAs (miRNAs) by targeting the proteins that interact with these molecules. Their innovative approach focuses on using short non-coding RNAs to inhibit gene expression, suppress mRNA translation, and promote mRNA decay. By targeting miRNAs that play a critical role in cancer initiation, progression, and metastasis, Twentyeight-Seven aims to create effective therapeutic solutions for cancer treatment.

ITeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics for cancer treatment. Founded in 2011 and headquartered in Gosselies, Belgium, with operational ties to Cambridge, Massachusetts, the company leverages its expertise in tumor immunology to create small molecule immunomodulators. Its product pipeline includes EOS-850, an antagonist of the adenosine A2a receptor, currently in an open-label Phase 1/2a clinical trial for adult patients, and EOS-448, which targets the TIGIT receptor and is also in a Phase 1/2a clinical trial. ITeos aims to enhance the effectiveness of cancer therapies by targeting resistance mechanisms within the tumor microenvironment, thereby improving the clinical outcomes of existing treatment modalities and newer immunotherapies.

TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company focused on developing innovative T cell receptor therapies for cancer treatment. The company's lead product candidates include TC-210, a TRuC-T cell therapy targeting mesothelin-positive solid tumors, which is currently undergoing a phase I/II clinical trial for various cancers, including non-small cell lung cancer, ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Another key candidate is TC-110, designed to target CD19-positive B-cell hematological malignancies. TCR2's pipeline also addresses adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma. The company, founded in 2015 and headquartered in Cambridge, Massachusetts, leverages advanced technologies and a deep understanding of T cell receptor biology to create therapies that differ from traditional CAR-T treatments and enhance T cell engagement in recognizing and destroying cancer cells.

Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who traditionally rely on insulin injections. Founded based on groundbreaking research by Professor Douglas Melton, the company has licensed a method to generate functional, insulin-producing beta cells in the laboratory. Semma Therapeutics aims to combine these proprietary cells with advanced devices to create a comprehensive therapy that can replace the missing beta cells without the need for immunosuppression. By striving to bring this transformative treatment to clinical application, Semma Therapeutics seeks to significantly enhance the lives of diabetes patients. Headquartered in Cambridge, Massachusetts, the company is a subsidiary of Vertex Pharmaceuticals and collaborates strategically with Defymed.

Cullinan Pearl, a subsidiary of Cullinan Oncology, focuses on developing innovative cancer therapies, specifically targeting Epidermal Growth Factor Receptor (EGFR) exon 20 mutations through its orally available tyrosine kinase inhibitor. The company is part of a broader strategy to create a diverse portfolio of oncology therapeutics, relying on a combination of internal research and collaborative efforts with academic institutions and pharmaceutical companies. This approach allows Cullinan Pearl to efficiently advance its drug development programs, with a commitment to rapidly discontinue any projects that show limited potential based on early research findings. As part of its ongoing initiatives, Cullinan Pearl collaborates with Cullinan Oncology to support the development and commercialization of its therapies.

Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who traditionally rely on insulin injections. Founded based on groundbreaking research by Professor Douglas Melton, the company has licensed a method to generate functional, insulin-producing beta cells in the laboratory. Semma Therapeutics aims to combine these proprietary cells with advanced devices to create a comprehensive therapy that can replace the missing beta cells without the need for immunosuppression. By striving to bring this transformative treatment to clinical application, Semma Therapeutics seeks to significantly enhance the lives of diabetes patients. Headquartered in Cambridge, Massachusetts, the company is a subsidiary of Vertex Pharmaceuticals and collaborates strategically with Defymed.

Rhythm Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing peptide therapeutics for the treatment of rare genetic disorders, particularly those leading to life-threatening metabolic conditions. Its primary product candidate, setmelanotide, is a first-in-class melanocortin-4 receptor agonist currently undergoing Phase III clinical trials for obesity related to pro-opiomelanocortin and leptin receptor deficiencies, as well as Bardet-Biedl and Alström syndromes. Additionally, setmelanotide is in Phase II trials for various other genetic obesity disorders. The company is also advancing RM-853, an orally available ghrelin O-acyltransferase inhibitor, in preclinical development for Prader-Willi syndrome. Founded in 2008 and headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals aims to address significant unmet medical needs in the realm of genetic metabolic disorders through innovative therapies.

TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company focused on developing innovative T cell receptor therapies for cancer treatment. The company's lead product candidates include TC-210, a TRuC-T cell therapy targeting mesothelin-positive solid tumors, which is currently undergoing a phase I/II clinical trial for various cancers, including non-small cell lung cancer, ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Another key candidate is TC-110, designed to target CD19-positive B-cell hematological malignancies. TCR2's pipeline also addresses adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma. The company, founded in 2015 and headquartered in Cambridge, Massachusetts, leverages advanced technologies and a deep understanding of T cell receptor biology to create therapies that differ from traditional CAR-T treatments and enhance T cell engagement in recognizing and destroying cancer cells.

Oncorus, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative viral immunotherapies for cancer treatment. The company's lead candidate, ONCR-177, utilizes an oncolytic herpes simplex virus type 1 platform and is currently in Phase I clinical trials aimed at treating various cancers. In addition to ONCR-177, Oncorus is advancing the ONCR-GBM program for brain cancer and exploring synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has entered a collaboration with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 in combination with Merck’s immunotherapy. Founded in 2015 and headquartered in Cambridge, Massachusetts, Oncorus is committed to advancing cancer care and has pledged to support cancer research and healthcare initiatives in developing regions through corporate philanthropy.

To this end, arGEN-X has invented and developed a breakthrough discovery platform setting the new standard for antibody lead choice in the discovery of human antibody therapeutics. Fuelled by the best possible natural immune responses available, our Simple Antibodyâ„¢ platform leapfrogs existing platforms in what is probably the most critical aspect of drug discovery and development: lead choice.

Twentyeight-Seven, Inc. is a biotechnology company based in Watertown, Massachusetts, specializing in the development of small molecules that modulate microRNAs (miRNAs) by targeting the proteins that interact with these molecules. Their innovative approach focuses on using short non-coding RNAs to inhibit gene expression, suppress mRNA translation, and promote mRNA decay. By targeting miRNAs that play a critical role in cancer initiation, progression, and metastasis, Twentyeight-Seven aims to create effective therapeutic solutions for cancer treatment.

Potenza Therapeutics, Inc. is a preclinical-stage biotechnology company based in Cambridge, Massachusetts, founded in 2014. The company focuses on developing a portfolio of oncology programs that harness the body's immune system to identify and eliminate tumors. Potenza's innovative approach is rooted in understanding the biological mechanisms by which cancer cells evade immune detection and destruction. By leveraging these insights, the company aims to create effective pharmaceuticals that enhance the health outcomes of cancer patients.

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of innovative cancer therapies. Its lead product candidate, entinostat, is a class I HDAC inhibitor currently undergoing Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, the company is developing SNDX-5613, an inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for specific types of acute leukemia. Syndax's pipeline also includes SNDX-6352, a monoclonal antibody designed to block the CSF-1 receptor, which is being tested for chronic graft versus host disease and various solid tumors. The company is pursuing multiple clinical collaborations and agreements with notable organizations, including MSD International and the National Cancer Institute, to enhance its research and development efforts. Founded in 2005, Syndax is dedicated to advancing treatment options for patients with solid tumors and hematological cancers.

Rhythm Metabolic is the subsidiary of Rhythm Pharmaceuticals that develops setmelanotide (RM-493), a novel peptide MC4 agonist for the treatment of obesity caused by genetic deficiencies in the MC4 pathway. It was established in 2013 and is headquartered in Boston, Massachusetts.

Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who traditionally rely on insulin injections. Founded based on groundbreaking research by Professor Douglas Melton, the company has licensed a method to generate functional, insulin-producing beta cells in the laboratory. Semma Therapeutics aims to combine these proprietary cells with advanced devices to create a comprehensive therapy that can replace the missing beta cells without the need for immunosuppression. By striving to bring this transformative treatment to clinical application, Semma Therapeutics seeks to significantly enhance the lives of diabetes patients. Headquartered in Cambridge, Massachusetts, the company is a subsidiary of Vertex Pharmaceuticals and collaborates strategically with Defymed.

Clinical Ink, Inc. specializes in providing eSource and patient engagement solutions tailored for the clinical research sector, assisting sites, sponsors, and contract research organizations (CROs) in streamlining their processes. The company's primary offering, SureSource, is an electronic source platform designed to capture essential clinical trial data and documents directly at the research site. Additionally, Clinical Ink provides Lunexis ePRO+, which facilitates patient participation by allowing flexible engagement options, and CentrosHealth, a platform that keeps patients informed and compliant throughout their clinical trial experience. Founded in 2006, Clinical Ink operates its headquarters in Horsham, Pennsylvania, and has additional offices in Winston-Salem, Cary, Philadelphia, and Cambridge. The company aims to enhance clinical trial workflows and improve data quality through its innovative electronic source solutions.

Chiasma (Israel) Ltd. is a biopharmaceutical company specializing in the development of oral drugs utilizing its proprietary Transient Permeability Enhancer technology. Founded in 2001 and based in Ness Ziona, Israel, the company focuses on transforming injectable drugs into oral formulations, thereby enhancing their absorption and potentially enabling new therapeutic indications. Its primary product is oral octreotide acetate, designed for the treatment of acromegaly, a rare condition. Chiasma's pipeline includes novel drugs aimed at addressing unmet medical needs in well-defined markets, with a particular emphasis on orphan indications. The company operates as a subsidiary of Chiasma, Inc., and is dedicated to improving the treatment options for patients with rare and debilitating diseases.

Raze Therapeutics focuses on discovering and developing innovative oncology therapeutics that target essential metabolic pathways crucial for cancer growth and survival. The company is advancing a pipeline of treatments based on novel biological insights into how cancer cells reprogram their metabolism to support tumor development. By selectively targeting one-carbon metabolism through a proprietary platform, Raze aims to provide patients with quicker access to treatment and improve the chances of successful outcomes.

Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases. The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics. Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).

Sideris Pharmaceuticals Inc. is a privately held biopharmaceutical company that is focused on development of therapeutics for the treatment of transfusion-related iron overload. The company’s operations include facilities in Boston, MA, and in Gainesville, FL.

Mitobridge, Inc., a biotechnology company, discovers and develops novel small molecule therapeutics that improve mitochondrial functions. Its product under pipeline includes MA-0211 (MTB-1), a clinical compound that is orally bioavailable PPARd modulator that aims to reverse the mitochondrial deficits in Duchenne muscular dystrophy patients. Mitobridge, Inc. was formerly known as Mitokyne, Inc. and changed its name to Mitobridge, Inc. in February 2015. The company was incorporated in 2011 and is based in Cambridge, Massachusetts. As of January 23, 2018, Mitobridge, Inc. operates as a subsidiary of Astellas Pharma Inc.

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of innovative cancer therapies. Its lead product candidate, entinostat, is a class I HDAC inhibitor currently undergoing Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, the company is developing SNDX-5613, an inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for specific types of acute leukemia. Syndax's pipeline also includes SNDX-6352, a monoclonal antibody designed to block the CSF-1 receptor, which is being tested for chronic graft versus host disease and various solid tumors. The company is pursuing multiple clinical collaborations and agreements with notable organizations, including MSD International and the National Cancer Institute, to enhance its research and development efforts. Founded in 2005, Syndax is dedicated to advancing treatment options for patients with solid tumors and hematological cancers.

Radius Health, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for osteoporosis and oncology. The company markets TYMLOS, an anabolic agent specifically for postmenopausal women with osteoporosis. It is advancing several clinical programs, including abaloparatide-SC, currently in phase 3 trials for treating osteoporosis in men, and a short-wear-time transdermal patch for postmenopausal women. Additionally, Radius is developing Elacestrant, a selective estrogen receptor degrader in phase 3 studies for hormone receptor-positive breast cancer, and RAD140, a selective androgen receptor modulator in phase 1A trials for metastatic breast cancer. Founded in 2003 and based in Waltham, Massachusetts, Radius Health collaborates with various organizations, including 3M Company and Duke University, to enhance its research and development efforts in bone health and women's health issues.

CoStim Pharmaceuticals Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing innovative antibody agents for cancer treatment. Founded in 2011, the company specializes in cancer immunotherapy, creating antibody drugs that target immunological checkpoint control mechanisms. By harnessing the body's immune response, CoStim aims to improve therapeutic options for patients with cancer.

Motus Therapeutics is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital and New Enterprise Associates. The company is based in Boston, Massachusetts.

Chiasma (Israel) Ltd. is a biopharmaceutical company specializing in the development of oral drugs utilizing its proprietary Transient Permeability Enhancer technology. Founded in 2001 and based in Ness Ziona, Israel, the company focuses on transforming injectable drugs into oral formulations, thereby enhancing their absorption and potentially enabling new therapeutic indications. Its primary product is oral octreotide acetate, designed for the treatment of acromegaly, a rare condition. Chiasma's pipeline includes novel drugs aimed at addressing unmet medical needs in well-defined markets, with a particular emphasis on orphan indications. The company operates as a subsidiary of Chiasma, Inc., and is dedicated to improving the treatment options for patients with rare and debilitating diseases.

Motus Therapeutics is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital and New Enterprise Associates. The company is based in Boston, Massachusetts.

Helicos BioSciences Corporation is a life sciences company that specializes in advanced genetic analysis technology. It has developed the True Single Molecule Sequencing (tSMS) technology, which allows for the rapid analysis of large amounts of genetic material by directly sequencing individual molecules of DNA and RNA. This innovative approach enables precise sequencing and offers significant advantages in research, drug discovery, and clinical diagnostics. The Helicos Genetic Analysis Platform includes the HeliScope Single Molecule Sequencer, which performs a series of biochemical reactions on single DNA or RNA molecules, and the HeliScope Analysis Engine, an image analysis computer system that processes the sequencing data. The platform also utilizes specialized reagents and disposable supplies essential for the sequencing process. Through its unique technology, Helicos aims to enhance the understanding of genetic information and improve applications in various fields of life sciences.

CoStim Pharmaceuticals Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing innovative antibody agents for cancer treatment. Founded in 2011, the company specializes in cancer immunotherapy, creating antibody drugs that target immunological checkpoint control mechanisms. By harnessing the body's immune response, CoStim aims to improve therapeutic options for patients with cancer.

Radius Health, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for osteoporosis and oncology. The company markets TYMLOS, an anabolic agent specifically for postmenopausal women with osteoporosis. It is advancing several clinical programs, including abaloparatide-SC, currently in phase 3 trials for treating osteoporosis in men, and a short-wear-time transdermal patch for postmenopausal women. Additionally, Radius is developing Elacestrant, a selective estrogen receptor degrader in phase 3 studies for hormone receptor-positive breast cancer, and RAD140, a selective androgen receptor modulator in phase 1A trials for metastatic breast cancer. Founded in 2003 and based in Waltham, Massachusetts, Radius Health collaborates with various organizations, including 3M Company and Duke University, to enhance its research and development efforts in bone health and women's health issues.

Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. Its portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote cancer cell survival and tumor growth.

Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases. The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics. Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).

Radius Health, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for osteoporosis and oncology. The company markets TYMLOS, an anabolic agent specifically for postmenopausal women with osteoporosis. It is advancing several clinical programs, including abaloparatide-SC, currently in phase 3 trials for treating osteoporosis in men, and a short-wear-time transdermal patch for postmenopausal women. Additionally, Radius is developing Elacestrant, a selective estrogen receptor degrader in phase 3 studies for hormone receptor-positive breast cancer, and RAD140, a selective androgen receptor modulator in phase 1A trials for metastatic breast cancer. Founded in 2003 and based in Waltham, Massachusetts, Radius Health collaborates with various organizations, including 3M Company and Duke University, to enhance its research and development efforts in bone health and women's health issues.

Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. Its portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote cancer cell survival and tumor growth.

Mitobridge, Inc., a biotechnology company, discovers and develops novel small molecule therapeutics that improve mitochondrial functions. Its product under pipeline includes MA-0211 (MTB-1), a clinical compound that is orally bioavailable PPARd modulator that aims to reverse the mitochondrial deficits in Duchenne muscular dystrophy patients. Mitobridge, Inc. was formerly known as Mitokyne, Inc. and changed its name to Mitobridge, Inc. in February 2015. The company was incorporated in 2011 and is based in Cambridge, Massachusetts. As of January 23, 2018, Mitobridge, Inc. operates as a subsidiary of Astellas Pharma Inc.

Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. Its portfolio consists of small molecule kinase inhibitors that inhibit critical signaling pathways, which promote cancer cell survival and tumor growth.

Motus Therapeutics is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital and New Enterprise Associates. The company is based in Boston, Massachusetts.

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of innovative cancer therapies. Its lead product candidate, entinostat, is a class I HDAC inhibitor currently undergoing Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, the company is developing SNDX-5613, an inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for specific types of acute leukemia. Syndax's pipeline also includes SNDX-6352, a monoclonal antibody designed to block the CSF-1 receptor, which is being tested for chronic graft versus host disease and various solid tumors. The company is pursuing multiple clinical collaborations and agreements with notable organizations, including MSD International and the National Cancer Institute, to enhance its research and development efforts. Founded in 2005, Syndax is dedicated to advancing treatment options for patients with solid tumors and hematological cancers.

Rhythm Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing peptide therapeutics for the treatment of rare genetic disorders, particularly those leading to life-threatening metabolic conditions. Its primary product candidate, setmelanotide, is a first-in-class melanocortin-4 receptor agonist currently undergoing Phase III clinical trials for obesity related to pro-opiomelanocortin and leptin receptor deficiencies, as well as Bardet-Biedl and Alström syndromes. Additionally, setmelanotide is in Phase II trials for various other genetic obesity disorders. The company is also advancing RM-853, an orally available ghrelin O-acyltransferase inhibitor, in preclinical development for Prader-Willi syndrome. Founded in 2008 and headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals aims to address significant unmet medical needs in the realm of genetic metabolic disorders through innovative therapies.

Motus Therapeutics is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm investors include MPM Capital and New Enterprise Associates. The company is based in Boston, Massachusetts.

Alnara Pharmaceuticals, Inc. specializes in the development and commercialization of novel protein therapeutics aimed at treating metabolic diseases. The company employs an innovative approach that emphasizes the design of effective protein therapies capable of being orally delivered directly to the gastrointestinal tract, ensuring they are not absorbed into the bloodstream. This unique method positions Alnara to address unmet medical needs in the realm of metabolic disorders through advanced therapeutic solutions.

Dragonfly Sciences specializes in the development of a new class of biosimilar products, focusing on complex monoclonal antibodies and soluble receptors. The company utilizes advanced biological tools and precision bioanalytics to create these products, ensuring they meet stringent regulatory standards for safety and efficacy. By addressing the needs of the biotechnology industry, Dragonfly Sciences aims to provide effective treatments for serious and life-threatening conditions, including cancer and autoimmune diseases.

PrimeraDx, Inc. specializes in multiplexed infectious disease assays, focusing on advanced diagnostic technologies. The company offers Scalable Target Amplification Routine technology, enabling the simultaneous quantitative measurement of multiple target nucleic acids. Its product lineup includes ViraQuant, a multiplexed assay for the quantitative measurement of various viruses, as well as FungiQuant Yeast and FungiQuant Mold, which are fungal panels used in mycology testing. Additionally, PrimeraDx provides an instrument designed for the simultaneous detection and quantification of diverse target types, such as mRNA, miRNA, SNPs, and DNA. These products are utilized in various applications, including miRNA analysis, DNA methylation, quantitative genotyping, gene expression, and viral load measurement. Founded in 2004, PrimeraDx is headquartered in Mansfield, Massachusetts.

Epizyme, Inc. is a late-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing epigenetic medicines for cancer and other diseases. The company has achieved a significant milestone with its approved product, Tazemetostat, which is used for treating metastatic or locally advanced epithelioid sarcoma in the United States. Additionally, Tazemetostat is being investigated in combination therapies for various cancers, including relapsed and refractory follicular lymphoma and high-risk diffuse large B-cell lymphoma. Epizyme is also engaged in developing other drug candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, alongside inhibitors targeting PRMT5 and PRMT1 for solid tumors and blood cancers. The company collaborates with several industry leaders and research organizations to advance its innovative therapeutic programs, reflecting its commitment to translating epigenetic research into effective treatments. Founded in 2007, Epizyme aims to reshape cancer treatment through its focus on molecularly targeted drugs.

Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases. The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics. Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).

Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.

Surface Logix is a drug development company specializing in the creation of small molecule drugs aimed at treating metabolic and cardiovascular diseases. Leveraging expertise in biophysical chemistry, the company develops new chemical entities that target specific tissues and organ systems, including the gastrointestinal and cardiovascular systems. Surface Logix focuses on enhancing pharmacokinetic and pharmacodynamic properties of its drugs, striving to offer significant improvements over existing therapies in these therapeutic areas. The company has multiple programs addressing various diseases, showcasing its commitment to advancing treatment options for patients.

Radius Health, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for osteoporosis and oncology. The company markets TYMLOS, an anabolic agent specifically for postmenopausal women with osteoporosis. It is advancing several clinical programs, including abaloparatide-SC, currently in phase 3 trials for treating osteoporosis in men, and a short-wear-time transdermal patch for postmenopausal women. Additionally, Radius is developing Elacestrant, a selective estrogen receptor degrader in phase 3 studies for hormone receptor-positive breast cancer, and RAD140, a selective androgen receptor modulator in phase 1A trials for metastatic breast cancer. Founded in 2003 and based in Waltham, Massachusetts, Radius Health collaborates with various organizations, including 3M Company and Duke University, to enhance its research and development efforts in bone health and women's health issues.

Innovative Spinal Technologies is a company focused on developing advanced solutions for spinal disorders, emphasizing motion preservation and minimally invasive treatments. Founded in 2002 and headquartered in Mansfield, Massachusetts, the company offers a range of products designed to enhance surgical outcomes. Key offerings include the AXIENT Dynamic Fixation system, a pedicle screw-based motion system, and the PARAMOUNT Lumbar Fusion System, which is adaptable for various surgical approaches, including minimally invasive and open procedures. Additionally, the PARAMOUNT MIS Pedicle Screw System caters to both single and multi-level spinal surgeries, while the PARAMOUNT Open Pedicle Screw System is tailored for minimally invasive lumbar fusion needs. The PARAMOUNT VBR system is specifically designed for minimally invasive transforaminal approaches, underscoring the company's commitment to innovative spinal care solutions.

Peptimmune is a privately held clinical stage biotechnology company focused on utilizing both novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders. The company is developing second generation therapeutics that are expected to result in safer and more effective products for obesity, multiple sclerosis, rheumatoid arthritis and pemphigus vulgaris.

Epizyme, Inc. is a late-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing epigenetic medicines for cancer and other diseases. The company has achieved a significant milestone with its approved product, Tazemetostat, which is used for treating metastatic or locally advanced epithelioid sarcoma in the United States. Additionally, Tazemetostat is being investigated in combination therapies for various cancers, including relapsed and refractory follicular lymphoma and high-risk diffuse large B-cell lymphoma. Epizyme is also engaged in developing other drug candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, alongside inhibitors targeting PRMT5 and PRMT1 for solid tumors and blood cancers. The company collaborates with several industry leaders and research organizations to advance its innovative therapeutic programs, reflecting its commitment to translating epigenetic research into effective treatments. Founded in 2007, Epizyme aims to reshape cancer treatment through its focus on molecularly targeted drugs.

Peptimmune is a privately held clinical stage biotechnology company focused on utilizing both novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders. The company is developing second generation therapeutics that are expected to result in safer and more effective products for obesity, multiple sclerosis, rheumatoid arthritis and pemphigus vulgaris.

PrimeraDx, Inc. specializes in multiplexed infectious disease assays, focusing on advanced diagnostic technologies. The company offers Scalable Target Amplification Routine technology, enabling the simultaneous quantitative measurement of multiple target nucleic acids. Its product lineup includes ViraQuant, a multiplexed assay for the quantitative measurement of various viruses, as well as FungiQuant Yeast and FungiQuant Mold, which are fungal panels used in mycology testing. Additionally, PrimeraDx provides an instrument designed for the simultaneous detection and quantification of diverse target types, such as mRNA, miRNA, SNPs, and DNA. These products are utilized in various applications, including miRNA analysis, DNA methylation, quantitative genotyping, gene expression, and viral load measurement. Founded in 2004, PrimeraDx is headquartered in Mansfield, Massachusetts.

Acceleron Pharma Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics for serious and rare diseases. The company is known for luspatercept-aamt, marketed as REBLOZYL, which treats anemia in adult patients with beta-thalassemia. Additionally, it is developing luspatercept-aamt for myelodysplastic syndromes and myelofibrosis, while Sotatercept targets pulmonary arterial hypertension. Acceleron is also advancing ACE-083, a neuromuscular candidate in Phase II trials aimed at Charcot-Marie-Tooth disease. The company's research focuses on biotherapeutics that influence the growth of bone, muscle, fat, and blood vessels to address conditions such as cancer-related bone and muscle loss, as well as various metabolic disorders. Founded in 2003 and based in Cambridge, Massachusetts, Acceleron has established collaborations with Celgene Corporation and Fulcrum Therapeutics to enhance its therapeutic offerings in the pulmonary disease space.

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of innovative cancer therapies. Its lead product candidate, entinostat, is a class I HDAC inhibitor currently undergoing Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, the company is developing SNDX-5613, an inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for specific types of acute leukemia. Syndax's pipeline also includes SNDX-6352, a monoclonal antibody designed to block the CSF-1 receptor, which is being tested for chronic graft versus host disease and various solid tumors. The company is pursuing multiple clinical collaborations and agreements with notable organizations, including MSD International and the National Cancer Institute, to enhance its research and development efforts. Founded in 2005, Syndax is dedicated to advancing treatment options for patients with solid tumors and hematological cancers.

Radius Health, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions for osteoporosis and oncology. The company markets TYMLOS, an anabolic agent specifically for postmenopausal women with osteoporosis. It is advancing several clinical programs, including abaloparatide-SC, currently in phase 3 trials for treating osteoporosis in men, and a short-wear-time transdermal patch for postmenopausal women. Additionally, Radius is developing Elacestrant, a selective estrogen receptor degrader in phase 3 studies for hormone receptor-positive breast cancer, and RAD140, a selective androgen receptor modulator in phase 1A trials for metastatic breast cancer. Founded in 2003 and based in Waltham, Massachusetts, Radius Health collaborates with various organizations, including 3M Company and Duke University, to enhance its research and development efforts in bone health and women's health issues.

Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.

Chiasma (Israel) Ltd. is a biopharmaceutical company specializing in the development of oral drugs utilizing its proprietary Transient Permeability Enhancer technology. Founded in 2001 and based in Ness Ziona, Israel, the company focuses on transforming injectable drugs into oral formulations, thereby enhancing their absorption and potentially enabling new therapeutic indications. Its primary product is oral octreotide acetate, designed for the treatment of acromegaly, a rare condition. Chiasma's pipeline includes novel drugs aimed at addressing unmet medical needs in well-defined markets, with a particular emphasis on orphan indications. The company operates as a subsidiary of Chiasma, Inc., and is dedicated to improving the treatment options for patients with rare and debilitating diseases.

Peptimmune is a privately held clinical stage biotechnology company focused on utilizing both novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders. The company is developing second generation therapeutics that are expected to result in safer and more effective products for obesity, multiple sclerosis, rheumatoid arthritis and pemphigus vulgaris.

Helicos BioSciences Corporation is a life sciences company that specializes in advanced genetic analysis technology. It has developed the True Single Molecule Sequencing (tSMS) technology, which allows for the rapid analysis of large amounts of genetic material by directly sequencing individual molecules of DNA and RNA. This innovative approach enables precise sequencing and offers significant advantages in research, drug discovery, and clinical diagnostics. The Helicos Genetic Analysis Platform includes the HeliScope Single Molecule Sequencer, which performs a series of biochemical reactions on single DNA or RNA molecules, and the HeliScope Analysis Engine, an image analysis computer system that processes the sequencing data. The platform also utilizes specialized reagents and disposable supplies essential for the sequencing process. Through its unique technology, Helicos aims to enhance the understanding of genetic information and improve applications in various fields of life sciences.

Hypnion is a neuroscience drug discovery and development company that develops novel therapeutics for the treatment of central nervous system disorders. The company develops treatments for sleep- and wake-alertness disorders and circadian rhythm abnormalities. Hypnion offers SCORE-2004, a drug discovery platform that is able to measure drugs’ impact on sleep and wake parameters. Hypnion is acquired by Eli Lilly and Company. Hypnion was founded in 2000 and is based in Worcester, Massachusetts.

Alinea Pharmaceuticals, Inc., a biopharmaceutical company previously focused on developing new therapeutics for the treatment of diabetes and other metabolic disorders.

Innovative Spinal Technologies is a company focused on developing advanced solutions for spinal disorders, emphasizing motion preservation and minimally invasive treatments. Founded in 2002 and headquartered in Mansfield, Massachusetts, the company offers a range of products designed to enhance surgical outcomes. Key offerings include the AXIENT Dynamic Fixation system, a pedicle screw-based motion system, and the PARAMOUNT Lumbar Fusion System, which is adaptable for various surgical approaches, including minimally invasive and open procedures. Additionally, the PARAMOUNT MIS Pedicle Screw System caters to both single and multi-level spinal surgeries, while the PARAMOUNT Open Pedicle Screw System is tailored for minimally invasive lumbar fusion needs. The PARAMOUNT VBR system is specifically designed for minimally invasive transforaminal approaches, underscoring the company's commitment to innovative spinal care solutions.

Peptimmune is a privately held clinical stage biotechnology company focused on utilizing both novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders. The company is developing second generation therapeutics that are expected to result in safer and more effective products for obesity, multiple sclerosis, rheumatoid arthritis and pemphigus vulgaris.

PrimeraDx, Inc. specializes in multiplexed infectious disease assays, focusing on advanced diagnostic technologies. The company offers Scalable Target Amplification Routine technology, enabling the simultaneous quantitative measurement of multiple target nucleic acids. Its product lineup includes ViraQuant, a multiplexed assay for the quantitative measurement of various viruses, as well as FungiQuant Yeast and FungiQuant Mold, which are fungal panels used in mycology testing. Additionally, PrimeraDx provides an instrument designed for the simultaneous detection and quantification of diverse target types, such as mRNA, miRNA, SNPs, and DNA. These products are utilized in various applications, including miRNA analysis, DNA methylation, quantitative genotyping, gene expression, and viral load measurement. Founded in 2004, PrimeraDx is headquartered in Mansfield, Massachusetts.

Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.

Critical Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing innovative products for respiratory and inflammatory diseases.

AVEO Oncology is a biopharmaceutical company engaged in the development and commercialization of targeted therapies for oncology and other unmet medical needs. The company's lead product, tivozanib, is an oral, once-daily inhibitor of vascular endothelial growth factor receptors, primarily indicated for renal cell carcinoma (RCC). AVEO has completed a Phase III trial (TIVO-3) for tivozanib and is conducting a Phase Ib/II trial combining it with Opdivo, an immune checkpoint inhibitor. Additionally, AVEO is developing Ficlatuzumab, an antibody currently in Phase II trials targeting various cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company's preclinical pipeline includes AV-380, aimed at cachexia, and AV-353, for pulmonary arterial hypertension. AVEO has established multiple collaboration agreements with various pharmaceutical companies and is involved in clinical trials assessing IMFINZI, an antibody targeting PD-L1. Headquartered in Boston, Massachusetts, AVEO was incorporated in 2001 and has a focus on advancing cancer therapeutics through its proprietary cancer biology platform.

Hypnion is a neuroscience drug discovery and development company that develops novel therapeutics for the treatment of central nervous system disorders. The company develops treatments for sleep- and wake-alertness disorders and circadian rhythm abnormalities. Hypnion offers SCORE-2004, a drug discovery platform that is able to measure drugs’ impact on sleep and wake parameters. Hypnion is acquired by Eli Lilly and Company. Hypnion was founded in 2000 and is based in Worcester, Massachusetts.

Peptimmune is a privately held clinical stage biotechnology company focused on utilizing both novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders. The company is developing second generation therapeutics that are expected to result in safer and more effective products for obesity, multiple sclerosis, rheumatoid arthritis and pemphigus vulgaris.

Critical Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing innovative products for respiratory and inflammatory diseases.

AVEO Oncology is a biopharmaceutical company engaged in the development and commercialization of targeted therapies for oncology and other unmet medical needs. The company's lead product, tivozanib, is an oral, once-daily inhibitor of vascular endothelial growth factor receptors, primarily indicated for renal cell carcinoma (RCC). AVEO has completed a Phase III trial (TIVO-3) for tivozanib and is conducting a Phase Ib/II trial combining it with Opdivo, an immune checkpoint inhibitor. Additionally, AVEO is developing Ficlatuzumab, an antibody currently in Phase II trials targeting various cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company's preclinical pipeline includes AV-380, aimed at cachexia, and AV-353, for pulmonary arterial hypertension. AVEO has established multiple collaboration agreements with various pharmaceutical companies and is involved in clinical trials assessing IMFINZI, an antibody targeting PD-L1. Headquartered in Boston, Massachusetts, AVEO was incorporated in 2001 and has a focus on advancing cancer therapeutics through its proprietary cancer biology platform.